Bill Gates-backed vaccine maker CureVac shares nearly triple in Nasdaq debut

Shares of German biotechnology firm CureVac nearly tripled in their Nasdaq debut Friday, marking the first stock market debut of a company developing a potential vaccine to combat the novel coronavirus. The stock opened at $44 per share, up from the initial public offering price of $16 per share. CureVac, backed by Microsoft founder and...